Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Raises Safety, Efficacy Concerns About Dendreon’s Cancer Vaccine Provenge

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory committee will discuss cerebrovascular accident as a safety signal for Provenge, as well as the biologic’s failure to meet primary efficacy endpoints.

You may also be interested in...



Advisory Committee Votes Favorably On Dendreon’s Prostate Cancer Vaccine

Though questions remain, majority of members find Provenge has “substantial evidence” of efficacy.

Advisory Committee Votes Favorably On Dendreon’s Prostate Cancer Vaccine

Though questions remain, majority of members find Provenge has “substantial evidence” of efficacy.

Sanofi Gains Therapeutic Cancer Vaccine TroVax In Deal With Oxford BioMedica

Announcement of the $690 million deal comes one day ahead of an advisory committee meeting for Provenge, the first therapeutic cancer vaccine to reach FDA.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel